ArticleScientific reports2026
Potential of non-specific blood biomarkers combined with EBV-specific antibodies for triaging in nasopharyngeal carcinoma screening.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although previous studies have indicated a link between Epstein-Barr virus (EBV) antibody positivity and increased risk of nasopharyngeal carcinoma (NPC), there is a lack of detailed analysis on the association between EBV antibody profile and various health examination indicators. In a retrospective cohort study involving 4,600 healthy subjects recruited from the physical examination center at Zhongshan City People’s Hospital (single-center), we collected demographic and EBV serological data. Levels of serum EBV antibodies were assessed through an enzyme-linked immunosorbent assay (ELISA). After controlling for age and sex, binary and ordinal logistic regressions were employed to compare the levels of health examination indicators between groups with different EBV antibody results. The levels of EBNA1-IgA, VCA-IgA, Zta-IgA, and Rta-IgG were significantly higher in the Positive group (positivity in any of the four EBV antibodies) compared to the Negative group (negativity of all four EBV antibodies). Additionally, the Positive group exhibited significant differences in several biochemical indicators compared to the Negative group. Binary and ordinal regressions constantly suggested that higher levels of globulin (GLO; OR = 1.03, 95% CI = 1.01–1.06) and carcinoembryonic antigen (CEA; OR = 1.07, 95% CI = 1.01–1.15), along with lower lymphocyte percentage (LYM%; OR = 0.99, 95% CI = 0.98–1.00) and low-density lipoprotein cholesterol (LDL-C; OR = 0.84, 95% CI = 0.77–0.92) were associated with higher EBV antibody seropositivity (p < 0.05). Integrating certain health examination indicators (such as GLO, CEA, and LYM%) with EBV antibody tests may serve as informative indicators, pending validation, to enhance screening accuracy for early NPC detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.